Oncoheroes Biosciences 11/11/21 Oncoheroes Biosciences 11/11/21 Oncoheroes Biosciences Inc. Out-licences volasertib to Notable Labs for the Global Adult Development of Its Anticancer Therapy Read More Oncoheroes Biosciences 2/15/21 Oncoheroes Biosciences 2/15/21 SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development, and Commercialization of Oncology Therapeutics For Rare Cancers Read More Oncoheroes Biosciences 10/14/20 Oncoheroes Biosciences 10/14/20 Volasertib, a potential new treatment for rhabdomyosarcoma, receives Orphan Drug Designation from the U.S. FDA Read More Oncoheroes Biosciences 9/24/20 Oncoheroes Biosciences 9/24/20 FDA Grants Rare Pediatric Disease Designation (RPDD) to volasertib for rhabdomyosarcoma Read More
Oncoheroes Biosciences 11/11/21 Oncoheroes Biosciences 11/11/21 Oncoheroes Biosciences Inc. Out-licences volasertib to Notable Labs for the Global Adult Development of Its Anticancer Therapy Read More
Oncoheroes Biosciences 2/15/21 Oncoheroes Biosciences 2/15/21 SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development, and Commercialization of Oncology Therapeutics For Rare Cancers Read More
Oncoheroes Biosciences 10/14/20 Oncoheroes Biosciences 10/14/20 Volasertib, a potential new treatment for rhabdomyosarcoma, receives Orphan Drug Designation from the U.S. FDA Read More
Oncoheroes Biosciences 9/24/20 Oncoheroes Biosciences 9/24/20 FDA Grants Rare Pediatric Disease Designation (RPDD) to volasertib for rhabdomyosarcoma Read More
